(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 August 2011 (11.08.2011)

PCT

(10) International Publication Number
WO 2011/095534 A1

(51) International Patent Classification:
A61K 31/18 (2006.01) *A61K 31/506* (2006.01)
A61K 31/194 (2006.01) *A61K 31/519* (2006.01)
A61K 31/427 (2006.01) *A61K 31/53* (2006.01)
A61K 31/4418 (2006.01) *A61K 45/06* (2006.01)
A61K 31/498 (2006.01) *A61P 11/00* (2006.01)
A61K 31/4985 (2006.01)

(21) International Application Number:
PCT/EP2011/051532

(22) International Filing Date:
3 February 2011 (03.02.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10152727.3 5 February 2010 (05.02.2010) EP

(71) Applicant *(for all designated States except US)*: **BAYER SCHERING PHARMA AKTIENGESELLSCHAFT** [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **SANDNER, Peter** [DE/DE]; Julius-Lucas-Weg 59, 42113 Wuppertal (DE). **VON DEGENFELD, Georges** [FR/DE]; Friedrich-Weskott-Str. 10, 51373 Leverkusen (DE). **STASCH, Johannes-Peter** [DE/DE]; Alfred-Nobel-Str.109, 42651 Solingen (DE).

(74) Common Representative: **BAYER SCHERING PHARMA AKTIENGESELLSCHAFT**; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2011/095534 A1

(54) **Title**: sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS

(57) **Abstract**: The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors. More particularly, the invention relates to the use of sGC stimulators and sGC activators in combination with PDE5 inhibitors for preparation of medicaments for the treatment of Cystic Fibrosis (CF).